FY2021 Q1 Financial Results Presentation

from the beginning

FY2021 Q1 Financial Results Presentation

Forward-Looking Statements

1. FY2021 Q1 Financial Results

Overview of FY2021 Q1 Results

Revenue

Core Operating Profit

Profit Attributable to Owners of the Company

Revenue: Business Units (incl. Forex Impact)

Revenue: Major Products in Japan

2. Business Update

ENHERTU(R): Revenue

ENHERTU(R): Performance in Each Region

Japan:New Product Approval

3. R&D Update

3ADCs update

ENHERTU(R):Breast cancer

ENHERTU(R):Gastric cancer

ENHERTU(R):NSCLC,CRC

Dato‐DXd:Breast cancer,NSCLC

HER3‐DXd: NSCLC

Alpha update

DS‐5670 (COVID‐19 mRNA vaccine)

DS‐3201 (EZH1/2 inhibitor):Presented interim results of NHL Ph1 study at EHA

DS‐3201 Ph1: Efficacy results

DS‐3201 Ph1:Most Common TEAEs

DS‐3201 ATL/PTCL development plan

Other Alpha update

WCLC/ESMO 2021

Planned Presentation at WCLC/ESMO 2021

News Flow

FY2021 News Flow

4. Appendix

Major R&D Milestones in FY2021 (3ADCs)

Major R&D Milestones in FY2021 (Alpha)

Major R&D Pipeline: 3ADCs

Major R&D Pipeline: Alpha

@

Q&A

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7